Literature DB >> 23313363

Percutaneous nephrolithotomy in children with cystine stone: long-term outcomes from a single institution.

Bulent Onal1, Cagatay Dogan, Sinharib Citgez, Burak Argun, Ali Ulvi Onder, Lale Sever, Salim Caliskan, Nur Canpolat, Mehmet Tasdemir, Ahmet Erozenci.   

Abstract

PURPOSE: We determined the effectiveness of percutaneous nephrolithotomy in children with cystine stones and present the long-term outcomes.
MATERIALS AND METHODS: We reviewed the data of 65 renal units in 51 children who underwent percutaneous nephrolithotomy for cystine stones between 2000 and 2012. Of the patients 19 (37%) had undergone ipsilateral renal surgery and 11 (22%) had undergone extracorporeal shock wave lithotripsy. Children were designated as being stone-free or having residual stone (any evidence of persistent stone fragments irrespective of size). Medical treatment with α-mercaptopropionylglycine, potassium citrate or potassium sodium hydrogen citrate was recommended for all patients after stone analysis.
RESULTS: Median stone burden was 3.3 cm(2) (range 1 to 13) and median patient age was 6 years (1 to 17). Stone-free status was achieved in 41 renal units (63.1%). Stone-free status was increased to 73.8% with additional endoscopic procedures. The remaining patients with residual stones were followed. Complication rate was 15.4%. A total of 35 children (68.6%) receiving regular medical treatment were followed for a median of 95 months (range 6 to 136). The recurrence rate for children achieving stone-free status was 31.2%, and the regrowth rate for children with residual stones was 29.4%.
CONCLUSIONS: Percutaneous nephrolithotomy is a safe and effective treatment for children with cystine stones. Our high recurrence and regrowth rates emphasize that our treatment schedule is inadequate to prevent recurrent cystine calculi. Additional investigation is needed to determine the optimal medical therapy for preventing recurrence and regrowth of cystine stones.
Copyright © 2013 American Urological Association Education and Research, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23313363     DOI: 10.1016/j.juro.2013.01.016

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  6 in total

1.  Multimodal treatments of cystine stones: an observational, retrospective single-center analysis of 14 cases.

Authors:  Myungsun Shim; Hyung Keun Park
Journal:  Korean J Urol       Date:  2014-08-08

2.  Is percutaneous nephrolithotomy effective and safe for children with solitary kidney?

Authors:  Kadir Karkin; Hakan Erçil
Journal:  Pediatr Surg Int       Date:  2022-06-15       Impact factor: 1.827

3.  Can cystinuria decrease the effectiveness of RIRS with high-power ho:yag laser in children? Outcomes from a tertiary endourology referral center.

Authors:  Yesica Quiroz Madarriaga; Almudena Badenes Gallardo; Erika Llorens de Knecht; Guilherme Motta Lang; Joan Palou Redorta; Anna Bujons Tur
Journal:  Urolithiasis       Date:  2022-01-27       Impact factor: 3.436

4.  Renal stone composition does not affect the outcome of percutaneous nephrolithotomy in children.

Authors:  Onur Kaygısız; Fethi Ahmet Türegün; Nihat Satar; Ender Özen; Serdar Toksöz; Hasan Serkan Doğan; Mehmet Mesut Pişkin; Volkan İzol; Şaban Sarıkaya; Hakan Kılıçarslan; Tufan Çiçek; Ahmet Öztürk; Serdar Tekgül; Bülent Önal
Journal:  World J Urol       Date:  2018-05-14       Impact factor: 4.226

5.  Percutaneous nephrolithotomy in children: A preliminary report.

Authors:  Ahmad A Elderwy; Mohamed Gadelmoula; Mohamed A Elgammal; Ehab Osama; Hamdan Al-Hazmi; H Hammouda; Esam Osman; Medhat A Abdullah; Khalid Fouda Neel
Journal:  Urol Ann       Date:  2014-07

6.  The challenge of cystine and struvite stone formers: clinical, metabolic and surgical assessment.

Authors:  Kleiton G R Yamaçake; Giovanni S Marchini; Sabrina Reis; Alexandre Danilovic; Fábio C Vicentini; Fábio C M Torricelli; Miguel Srougi; Eduardo Mazzucchi
Journal:  Int Braz J Urol       Date:  2016-09-01       Impact factor: 1.541

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.